Heidi Sankala

2.2k total citations · 1 hit paper
28 papers, 1.7k citations indexed

About

Heidi Sankala is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Heidi Sankala has authored 28 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 9 papers in Oncology and 9 papers in Hematology. Recurrent topics in Heidi Sankala's work include Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Sphingolipid Metabolism and Signaling (6 papers). Heidi Sankala is often cited by papers focused on Histone Deacetylase Inhibitors Research (9 papers), Protein Degradation and Inhibitors (7 papers) and Sphingolipid Metabolism and Signaling (6 papers). Heidi Sankala collaborates with scholars based in United States, Germany and Japan. Heidi Sankala's co-authors include Sheldon Milstien, Sarah Spiegel, Michael Maceyka, Nitai C. Hait, Rachelle E. Toman, Paul R. Graves, Hervé Le Stunff, Hong Liu, Min Zhang and Leslie S. Satin and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Heidi Sankala

28 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SphK1 and SphK2, Sphingosine Kinase Isoenzymes with Opposing Functions in Sphingolipid Metabolism

2005 530 citations Michael Maceyka, Heidi Sankala et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heidi Sankala United States	15	1.6k	604	179	176	173	28	1.7k
Dmitri Kapitonov United States	17	1.2k 0.7×	410 0.7×	144 0.8×	118 0.7×	273 1.6×	24	1.4k
Deanna M. Stevens United States	7	1.4k 0.9×	254 0.4×	175 1.0×	120 0.7×	214 1.2×	7	1.6k
Yonghong Xiao United States	10	1.6k 1.0×	337 0.6×	128 0.7×	282 1.6×	159 0.9×	12	1.9k
Matthew N. Hodgkin United Kingdom	16	1.2k 0.7×	419 0.7×	196 1.1×	103 0.6×	198 1.1×	32	1.5k
Greg M. Findlay United Kingdom	15	1.7k 1.1×	228 0.4×	261 1.5×	137 0.8×	185 1.1×	30	2.0k
John J. Upson United States	10	1.2k 0.8×	378 0.6×	85 0.5×	190 1.1×	147 0.8×	11	1.5k
Sahar A. Saddoughi United States	11	1.0k 0.7×	275 0.5×	161 0.9×	131 0.7×	105 0.6×	38	1.4k
Valeria Bertagnolo Italy	25	1.5k 1.0×	356 0.6×	159 0.9×	256 1.5×	202 1.2×	85	2.0k
Shane Minogue United Kingdom	24	1.1k 0.7×	660 1.1×	214 1.2×	120 0.7×	144 0.8×	36	1.6k
Astrid Eder United States	14	1.3k 0.8×	293 0.5×	93 0.5×	233 1.3×	308 1.8×	17	1.6k

Countries citing papers authored by Heidi Sankala

Since Specialization

Citations

This map shows the geographic impact of Heidi Sankala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Sankala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Sankala more than expected).

Fields of papers citing papers by Heidi Sankala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Sankala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Sankala. The network helps show where Heidi Sankala may publish in the future.

Co-authorship network of co-authors of Heidi Sankala

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Sankala. A scholar is included among the top collaborators of Heidi Sankala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Sankala. Heidi Sankala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shafer, Danielle, Michelle A. Rudek, Maciej Kmieciak, et al.. (2023). Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. Cancer Chemotherapy and Pharmacology. 91(3). 281–290. 14 indexed citations

Fields, Emma C., Brian Kaplan, Jeremy Karlin, et al.. (2019). Phase 1 Study of Neoadjuvant Short-Course Radiation Therapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer. Advances in Radiation Oncology. 4(4). 605–612. 3 indexed citations

Holkova, Beata, Jeffrey G. Supko, Matthew M. Ames, et al.. (2013). A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2. Clinical Cancer Research. 19(7). 1873–1883. 26 indexed citations

Holkova, Beata, Thomas C. Shea, Prithviraj Bose, et al.. (2012). Phase I Study of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Lymphoma, or Peripheral T-Cell Lymphoma. Blood. 120(21). 1794–1794. 4 indexed citations

Holkova, Beata, Prithviraj Bose, Daniel M. Sullivan, et al.. (2012). Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.. Blood. 120(21). 2959–2959. 1 indexed citations

Sankala, Heidi, Catherine A. Vaughan, Jing Wang, Sumitra Deb, & Paul R. Graves. (2011). Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Archives of Biochemistry and Biophysics. 512(1). 52–60. 30 indexed citations

Vaughan, Catherine A., Shilpa Singh, Brad E. Windle, et al.. (2011). p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Archives of Biochemistry and Biophysics. 518(1). 79–88. 49 indexed citations

Holkova, Beata, Lubomir Sokol, Kristy L. Richards, et al.. (2011). A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma. Blood. 118(21). 779–779. 9 indexed citations

Holkova, Beata, Ashraf Badros, Robert B. Geller, et al.. (2011). A Phase II Study of the MEK 1/2 Inhibitor AZD6244 (Selumetinib, ARRY-142866) in Relapsed or Refractory Multiple Myeloma. Blood. 118(21). 2931–2931. 3 indexed citations

10.

Graves, Paul R., et al.. (2011). Upregulation of the Mitochondrial Transport Protein, Tim50, by Mutant P53 Contributes to Cell Growth and Chemoresistance. International Journal of Radiation Oncology*Biology*Physics. 81(2). S55–S56. 1 indexed citations

11.

Yakovlev, Vasily A., Heidi Sankala, Katharina Fleckenstein, et al.. (2010). Proteomic Analysis of Radiation-Induced Changes in Rat Lung: Modulation by the Superoxide Dismutase Mimetic MnTE-2-PyP5+. International Journal of Radiation Oncology*Biology*Physics. 78(2). 547–554. 14 indexed citations

12.

Zeng, Yan, Heidi Sankala, Xiaoxiao Zhang, & Paul R. Graves. (2008). Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies. Biochemical Journal. 413(3). 429–436. 175 indexed citations

13.

Sankala, Heidi, Nitai C. Hait, Steven W. Paugh, et al.. (2007). Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin. Cancer Research. 67(21). 10466–10474. 132 indexed citations

14.

Graves, Paul R., Heidi Sankala, & Z. Vujaskovic. (2007). Effect of Ionizing Radiation on Rat Lung Tissue: A Proteomic Analysis. International Journal of Radiation Oncology*Biology*Physics. 69(3). S618–S618. 1 indexed citations

15.

Sarkar, Sukumar, Michael Maceyka, Nitai C. Hait, et al.. (2005). Sphingosine kinase 1 is required for migration, proliferation and survival of MCF‐7 human breast cancer cells. FEBS Letters. 579(24). 5313–5317. 177 indexed citations

16.

Maceyka, Michael, Heidi Sankala, Nitai C. Hait, et al.. (2005). SphK1 and SphK2, Sphingosine Kinase Isoenzymes with Opposing Functions in Sphingolipid Metabolism. Journal of Biological Chemistry. 280(44). 37118–37129. 530 indexed citations breakdown →

17.

Jolly, Puneet S., Meryem Bektas, Kenneth R. Watterson, et al.. (2005). Expression of SphK1 impairs degranulation and motility of RBL-2H3 mast cells by desensitizing S1P receptors. Blood. 105(12). 4736–4742. 52 indexed citations

18.

Liu, Hong, Rachelle E. Toman, Sravan K. Goparaju, et al.. (2003). Sphingosine Kinase Type 2 Is a Putative BH3-only Protein That Induces Apoptosis. Journal of Biological Chemistry. 278(41). 40330–40336. 309 indexed citations

19.

Watterson, Kenneth R., Heidi Sankala, Sheldon Milstien, & Sarah Spiegel. (2003). Pleiotropic actions of sphingosine-1-phosphate. Progress in Lipid Research. 42(4). 344–357. 88 indexed citations

20.

Cartee, Leanne, Zhiliang Wang, Roy H. Decker, et al.. (2001). The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.. PubMed. 61(6). 2583–91. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact